Actively Recruiting
Phase 2 Study of Venetoclax for Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Led by AbbVie · Updated on 2025-12-24
110
Participants Needed
31
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the efficacy of venetoclax in adults with relapsed or refractory Chronic Lymphocytic Leukemia CLL or Small Lymphocytic Lymphoma SLL. This Phase 2, open-label, multicenter study focuses on two groups those with 17p deletion Cohort 1 and those who have failed B-cell receptor signaling pathway inhibitor therapy and either failed or cannot receive chemoimmunotherapy regardless of 17p status Cohort 2. Participants in both cohorts will receive various doses of venetoclax tablets taken once daily. The study does not involve a placebo group and uses a non-randomized approach. Treatment is tailored based on the participants disease characteristics and prior therapy history. During the study, researchers will monitor participants closely, assessing overall response rate up to two years after enrollment ends. Secondary measures include complete response rate, duration of response, progression-free survival, event-free survival, time to progression, time to lymphocyte count reduction, and overall survival, with some measures tracked up to five years. Participants will undergo regular evaluations to measure treatment effects and safety throughout the study.
CONDITIONS
Brief Title
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
